Capricor Therapeutics is trading 9.83% up at $9.11 as investors continue reacting to the FDA’s August 24 decision to extend deramiocel’s PDUFA deadline to November 22, 2026.
- The additional review period follows submission of new HOPE-3 data and analyses supporting a narrower potential indication.
- The move extends gains of 21.91% on August 25 and 8.11% on August 24, with broader biotech strength providing additional support.